A Phase 1/1b, clinical study of IVX-121 as a potential vaccine for respiratory syncytial virus (RSV) in healthy adults, including older adults
Latest Information Update: 11 Aug 2023
At a glance
- Drugs IVX-121 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Icosavax
- 08 Aug 2023 Results from Phase 1b extension 12-month immunogenicity and Phase 1b extension trial revaccination data presented in an Icosavax media release.
- 13 Dec 2022 According to an Icosavax media release, the company intends to present additional data at a future medical meeting.
- 13 Dec 2022 Six-month immunogenicity data published in an Icosavax Media Release.